Why participation in an international clinical trial platform matters during a pandemic? Launching REMAP-CAP in Japan

Kazuhiro Kamata, Kazuaki Jindai, Nao Ichihara, Hiroki Saito, Hideaki Kato, Hiroyuki Kunishima, Ayumi Shintani, Osamu Nishida, Shigeki Fujitani

Research output: Contribution to journalLetterpeer-review

Abstract

REMAP-CAP, a randomized, embedded, multifactorial adaptive platform trial for community-acquired pneumonia, is an international clinical trial that is rapidly expanding its scope and scale in response to the COVID-19 pandemic. Japan is now joining REMAP-CAP with endorsement from Japanese academic societies. Commitment to REMAP-CAP can significantly contribute to population health through timely identification of optimal COVID-19 therapeutics. Additionally, it will promote the establishment of a national and global network of clinical trials to tackle future pandemics of emerging and re-emerging infectious diseases, in collaboration with multiple stakeholders, including front-line healthcare workers, governmental agencies, regulatory authorities, and academic societies.

Original languageEnglish
Article number34
JournalJournal of Intensive Care
Volume9
Issue number1
DOIs
Publication statusPublished - 2021 Dec
Externally publishedYes

Keywords

  • COVID-19
  • Embedded
  • Emerging infectious disease
  • Multifactorial Adaptive Platform Trial for Community-Acquired Pneumonia)
  • REMAP-CAP (Randomized
  • Randomized controlled trial

ASJC Scopus subject areas

  • Critical Care and Intensive Care Medicine

Fingerprint

Dive into the research topics of 'Why participation in an international clinical trial platform matters during a pandemic? Launching REMAP-CAP in Japan'. Together they form a unique fingerprint.

Cite this